For women who require treatment with quetiapine during pregnancy, the available reproductive safety data are generally reassuring. The largest body of evidence does not suggest a meaningful increase in major congenital malformations, while metabolic effects, particularly gestational diabetes, remain an important consideration.
New registry data found no major malformations among 58 infants exposed to cariprazine in the first trimester, offering reassuring but preliminary reproductive safety evidence.
The current study observed no significant differences in overall developmental outcomes or behavior in exposed versus unexposed children.
Understanding important differences between men and women in terms of response to antipsychotic medications is essential to improving outcomes and decreasing risk for side effects.
This register-based cohort study from Denmark of 503,158 clinically recognized pregnancies observed little or no risk of teratogenesis associated with first trimester exposure to antipsychotic medications.
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
In this retrospective study of Taiwanese women using antipsychotic medications there was no observed increase in risk of metabolic complications.
Two studies - one using neuropsychological assessments, another examining performance on standardized testing - show no association between prenatal antipsychotic exposure and neurodevelopmental outcomes.
In a cohort of 351 children exposed to second generation antipsychotic during pregnancy, the risk of major congenital malformations did not differ from a comparison group of non-exposed children.
Prenatal exposure to antipsychotic medications was not associated with increased risk of neurodevelopmental disorders in offspring.
